      Document 0060
 DOCN  DRG0060
 UNIQUE IDENTIFIER        DRG-0187
 NAME OF SUBSTANCE        Thymic humoral factor [Facts and Comparisons
                          1995]
 SYNONYMS                 THF [AmFAR Tx Dir 1995;7(4)]
 SYNONYMS                 THF-gamma 2 [FDA 136A]
 PROTOCOL ID NUMBERS      FDA 136A
 IND NUMBER               31,822
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: THF is reported to increase
                          the number of T-lymphocytes and augment
                          cell-mediated immunity. [Int Conf AIDS 1993
                          Jun 6-11;9(1)] [AmFAR Tx Dir 1995;7(4)]
 DISEASES STUDIED/TREATED Enhancement of immune response in HIV
                          infection [AmFAR Tx Dir 1995;7(4)]
 CLASSIFICATION CODE      Immunomodulator [AmFAR Tx Dir 1995;7(4)]
 ADVERSE EFFECTS          Mild fatigue and reduced mental acuity have
                          been reported [AmFAR Tx Dir 1995;7(4)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: THF is a natural peptide
                          hormone isolated from calf thymus [AmFAR Tx
                          Dir 1993;6(4)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: THF-gamma 2 is a member of
                          the general class of thymus-derived compounds
                          and is a synthetic octapeptide [AmFAR Tx Dir
                          1993;6(4)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: This octapeptide has
                          demonstrated both in vitro and in vivo
                          immunomodulatory properties [AmFAR Tx Dir
                          1993;6(4)]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: 500 ng or 40 microgram dose.
                          [FDA 136A]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Intramuscular injection.
                          [AmFAR Tx Dir 1995;7(4)]
 MANUFACTURERS            Adria Laboratories
 REFERENCES               Clayette P, Chassard D, Marce D, Toutain B,
                          Thebault JJ, Lebeaut A, Dormont D. THF-gamma
                          2 phase I study in healthy volunteers. Int
                          Conf AIDS. 1993 Jun 6-11;9(1):246 (abstract
                          no. PO-A28-0671).
 REFERENCES               Calenda V, Silvy F, Chermann JC. Effects of
                          thymus humoral factor gamma-2 (THF gamma 2)
                          on lymphohaematopoietic progenitor cells: an
                          in vitro study. Res Immunol. 1993
                          Jul-Sep;144(6-7):395-406.
 REFERENCES               Kouttab N, Accetta G, Calabresi P, Skowron G.
                          Phase I trial of intramuscular (IM) thymic
                          humoral factor (THF) in combination with
                          zidovudine (ZDV) in HIV infected individuals.
                          Int Conf AIDS. 1992 Jul 19-24;8(2):B161
                          (abstract no. PoB 3447).
 REFERENCES               Trainin N. Prospects of AIDS therapy by
                          thymic humoral factor, a thymic hormone. Nat
                          Immun Cell Growth Regul. 1990;9(3):155-9.
 REFERENCES               Luzi G, Pesce AM, De Luca S, Carlesimo M,
                          Aiuti F. VIRAL INFECTIONS AND THYMIC
                          HORMONES: A NEW THERAPEUTIC APPROACH. Serono
                          Symp Publ Raven Press. 1989;59:291-302.
 REFERENCES               Handzel ZT, Berner Y, Segal O, Burstein Y,
                          Buchner V, Pecht M, Levin S, Burstein R,
                          Milchan R, Bentwich Z, et al.
                          Immunoreconstitution of T-cell impairments in
                          asymptomatic male homosexuals by thymic
                          humoral factor (THF). Int J Immunopharmacol.
                          1987;(2):165-73.
 ENTRY MONTH              9309
 LAST REVISION DATE       960310
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
